--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD-- SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on baseline characteristics for the global INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD) at the Alzheimer's Association International Conference® 2024 (AAIC®).

--INVOKE-2是第一个评估TREM2激动剂AL002在减缓早期阿尔茨海默氏病（AD）患者疾病进展方面的安全性和有效性的全球2期临床试验----INVOKE-2研究的基线特征数据证实了一个具有代表性的研究人群，该研究人群能够测试一种新型TREM2激动剂在AD早期的作用----加利福尼亚州南旧金山，2024年7月28日（全球通讯社）--Alector，Inc.（纳斯达克股票代码：ALEC），一家开创免疫神经病学的临床阶段生物技术公司，今天宣布发布一张关于全球INVOKE-2期临床试验基线特征的海报，评估AL002在减缓早期阿尔茨海默氏病患者疾病进展方面的安全性和有效性阿尔茨海默病协会2024年国际会议（AAIC®）上的阿尔茨海默病（AD）。

The conference is being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. INVOKE-2 is the first global Phase 2 trial exploring a novel TREM2 agonist, AL002, in early AD. AL002 is an investigational humanized monoclonal antibody (mAb) that binds to triggering receptor expressed on myeloid cells 2 (TREM2), and it is the most advanced TREM2 agonist product candidate in clinical trials.

会议于2024年7月28日至8月1日在宾夕法尼亚州费城举行。INVOKE-2是第一个在AD早期探索新型TREM2激动剂AL002的全球2期临床试验。AL002是一种研究性人源化单克隆抗体（mAb），与髓样细胞2（TREM2）上表达的触发受体结合，是临床试验中最先进的TREM2激动剂候选产品。

The candidate is being developed in collaboration with AbbVie. 'The baseline characteristics of the patients in INVOKE-2 are important for assessing the quality of our double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety and efficacy of AL002, the most advanced TREM2-activating candidate in clinical development for early Alzheimer’s disease,” said Gary Romano, M.D., Ph.D., Chief Medical Officer of Alector.

候选人正在与AbbVie合作开发。”。

“We are pleased that the baseline clinical assessments confirm that the INVOKE-2 trial enrolled the intended .

“我们很高兴基线临床评估证实INVOKE-2试验符合预期。